Table 2 ROC analysis for overall survival

From: Mixed lineage kinase ZAK promotes epithelial–mesenchymal transition in cancer progression

Variables

AUC (%)a

SE (95% CI)

P-valueb

Increased prognostic values (%)c

Individual parameters

Primary tumor stage (pT1–2 vs. pT3)

52.47

11.1(30.68–74.25)

0.7626

 

AJCC classification (I-II vs. III)

60.12

5.42 (49.51–70.74)

0.05179

 

LN (pN0–1 vs. pN2–3)

61.07

5.43 (50.42–71.72)

0.03645

 

HER2

61.38

5.08 (51.42–71.34)

0.03425

 

ER

64.55

5.35 (54.06–75.04)

0.006993

 

PR

66.41

4.77 (57.05–75.76)

0.001573

 

ZAK

69.67

4.54 (60.78–78.57)

0.001328

 

Combined markers

ER, PR,and HER2 (Basal type vs. other types)

68.63

6.30 (56.28–80.98)

0.007054

 

ZAK and HER2

69.76

6.05 (59.70–81.62)

0.002082

8.38

ZAK and pT

73.24

11.80 (50.09–96.38)

0.02101

20.77

ZAK and PR

73.41

5.37 (62.89–83.94)

0.0001728

7.00

ZAK and ER

75.45

5.79 (64.11–86.80)

0.0001334

10.90

ZAK and AJCC classification

77.70

6.38 (65.20–90.21)

0.0001750

17.58

ZAK and pN

78.79

6.43 (66.18–91.41)

0.0001223

17.72

ZAK, ER, PR, and HER2

80.18

6.52(67.39–92.97)

0.0001487

11.55

  1. ROC receiver operating curve, AUC area under the curve, SE standard error, 95% CI 95% confidence intervals
  2. aThe prognostic ability was evaluated by AUC. The AUC values range from 50 to 100%. The larger the AUC values, the more accurate the markers
  3. bROC curve analysis between AUC of indicated parameter and AUC = 50% (no prognostic value)
  4. cIncreased prognostic values = AUC of combined markers—AUC of corresponding individual markers (without combination of ZAK)
Back to article page